Mani Kavuru, MD

Contact Dr. Kavuru

834 Walnut Street
Ste. 650
Philadelphia, PA 19107

(215) 955-5161
(215) 923-6003 (fax)

Medical School
Northeastern Ohio Universities College of Medicine - 1984

Residency
Cleveland Clinic

Fellowship
Cleveland Clinic

Board Certification
Pulmonary Disease
Critical Care Medicine
Internal Medicine

Hospital Appointment
Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital

University Appointment
Professor of Medicine, 2010

Research and Clinical Interests
Asthma, Sarcoidosis, Pulmonary Alveolar Proteinosis and rare lung disease, pulmonary function testing, fellow education and research, bronchoscopy, and critical care

I am a pulmonary & critical care clinician scientist with a long-standing interest and experience in a variety of lung disorders, translational research, and multi-center clinical trials. I am the division director and am responsible for growing a robust academic pulmonary & critical care program that excels both regionally and nationally. I am board-certified in both pulmonary & critical care medicine and I am a Professor at Thomas Jefferson University / Hospital in center city Philadelphia. I trained at The Cleveland Clinic Foundation and was on faculty there for 14 years, and was the director of the PFT lab for 10 years. I was instrumental in starting the Sarcoidosis Center at CCF. I have an active clinical practice at Jefferson in both the outpatient setting as well as the hospital medical ICU. I am a co-director of the Jefferson Center for Critical Care. In these administrative capacities, I am involved in critical care from an organizational perspective and closely interface with intensivists from several disciplines as well as the emergency department. I have been a PI on a variety of pulmonary clinical trials over 20 years ranging from asthma, sarcoidosis, sepsis, ARDS, and pulmonary alveolar proteinosis. I have participated in a variety of NIH-funded consortia [i.e. Sarcoid Genetic Analysis (SAGA) consortium, Rare Lung Disease Consortium] and a variety of RO-1s as a co-investigator or a PI on the parent trials. Currently, I am a co-investigator on a pharma-funded sepsis study and an ARDS study and I have been the PI on several prior multi-center studies. I have authored or co-authored over 100 original publications. I have co-mentored 3 junior faculty in NIH K awards. Overall goal for our division is to provide world-class patient care with compassion, train the best pulmonary physicians, and contribute to advances for the future of our specialty. We wish to do this by broad-based collaborations & partnerships in a collegial atmosphere.

Publications

Most recent Peer-reviewed Publications

1. Extracorporeal membrane oxygenation to support whole-lung lavage in pulmonary alveolar proteinosis salvage of the drowned lungs
2. Alveolar macrophage cathelicidin deficiency in severe sarcoidosis
3. Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis
4. Alveolar macrophage activation in obese patients with obstructive sleep apnea
5. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis
6. Novel murine model of chronic granulomatous lung inflammation elicited by carbon nanotubes
7. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis
8. Restoration of PPARγ reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice
9. Sleep and metabolism: An overview
10. Montelukast added to fluticasone propionate does not alter inflammation or outcomes
11. Targeted PPARγ deficiency in alveolar macrophages disrupts surfactant catabolism
12. PPARγ regulates the expression of cholesterol metabolism genes in alveolar macrophages
13. Alveolar proteinosis syndrome: Pathogenesis, diagnosis, and management
14. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: Comparison of different methods of evaluation
15. Deletion of PPARγ in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response
16. A novel 1,25-dihydroxyvitamin D - Activin A pathway in human alveolar macrophages is dysfunctional in patients with pulmonary alveolar proteinosis (PAP)
17. Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial
18. ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis
19. Gene-environment interactions in sarcoidosis: challenge and opportunity
20. Characterization of a human surfactant protein A1 (SP-A1) gene-specific antibody; SP-A1 content variation among individuals of varying age and pulmonary health

View All Publications